Translational & Clinical Research
- Drug Discovery & Preclinical
- Monoclonal Antibodies
- Antibody-Drug Conjugates
- Vaccines (Prophylactic & Therapeutic)
- Cell & Gene Therapies (CGT)
- Allergy & Hypersensitivity
- Biomarker
- High-Dimensional Single-Cell Analysis by Flow Cytometry
- High-Throughput Cytokine & Chemokine Profiling by Multiplexing
- Biomarkers via Advanced IHC & Spatial Imaging
- Rare Cellular Functional Biomarkers by ELISPOT
- Real-Time Kinetic Biomarkers by IncuCyte S3
- Genomic Biomarker Analysis by qPCR & Droplet Digital PCR
- Seahorse XF: Immunometabolism & Bioenergetics
- MALDI Biotyper: Rapid Microbial & Proteomic Profiling
- Sapidyne KinExA
- Robust Protein Quantification by ELISA
- Advanced LNP Formulation & Screening – Unchained Labs Sunshine
- Translational & Clinical Research
- Immunogenicity Risk Assessment & Immunotoxicology
- Regulated Bioanalysis: PK, PD & Soluble Biomarkers
- Histopathology & Spatial Biology
- Advanced Flow Cytometry & Cellular Immunology
- Molecular Bioanalysis & Genomic Profiling
- Functional Potency & Ex Vivo Translational Models
- Central Laboratory & Clinical Trial Sample Management
- Dermo-Cosmetics & FMCG
- Nutraceuticals & Wellness
- Biorepository
Accelerating the Continuum from Preclinical Discovery to Clinical Proof-of-Concept
ImmunitasBio provides end-to-end, high-complexity translational, bioanalytical, pathology, and immunomonitoring services to biotechnology and pharmaceutical innovators worldwide. Combining specialized technical platforms with rigorous regulatory alignment (GLP/GCLP compliance), we provide actionable, mechanism-reflective data to de-risk candidate therapeutics, substantiate safety profiles, and validate clinical efficacy.
Integrated Modality Solutions
Therapeutic Modality |
Primary Translational Challenges Addressed |
Core Service Packages |
Immuno-Oncology |
TME immunosuppression, target engagement, CRS toxicity, durable response monitoring. |
High-parameter flow cytometry, multiplex IHC spatial mapping, Incucyte live-cell tumor killing, ELISPOT, soluble cytokine panels. |
Biologics & Bispecifics |
Immunogenicity (ADA/NAb), off-target cross-reactivity, effector function validation. |
Multi-tiered ADA & cell-based NAb assays, GLP-aligned TCR IHC, PK/PD assays, MOA-reflective potency testing (ADCC/CDC). |
Cell & Gene Therapy (CGT) |
In vivo persistence, vector biodistribution, VCN quantification, target tissue expression. Immunogenicity (ADA/NAb). |
dPCR VCN and biodistribution, RNAscope ISH, MHC multimer flow tracking, transgene IHC, standardized PBMC cryopreservation. Multi-tiered ADA & cell-based NAb assays. |
Peptide & Oligo Therapies |
Rapid metabolic clearance, immunogenicity risks of generic/novel peptides, receptor binding. |
High-sensitivity bioanalysis, peptide immunogenicity risk profiling, MHC binding/competition assays, target receptor localization IHC. |
Vaccines |
Cellular immunogenicity & memory profiling, humoral efficacy & neutralizing antibody generation, long-term durability, reactogenicity, and vector biodistribution. |
T-cell & B-cell ELISPOT, bespoke ELISA for Ig titers, cell-based NAb assays, high-parameter flow cytometry for polyfunctional profiling, AIM assay, Luminex cytokine panels, and ddPCR biodistribution. |